Celldex Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1983-01-01
- Employees
- 160
- Market Cap
- $2.5B
- Website
- http://www.celldex.com
Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
Phase 1
Completed
- Conditions
- Breast CancerColorectal CancerPancreatic CancerBladder CancerOvarian Cancer
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2010-07-26
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT00648102
- Locations
- 🇺🇸
Carolina BioOncology Institute, Huntersville, North Carolina, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
🇺🇸Duke University, Durham, North Carolina, United States
Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 82
- Registration Number
- NCT00458601
- Locations
- 🇺🇸
Celldex Investigational Site, Seattle, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath